Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison
2018 ◽
Vol 21
(3)
◽
pp. 710-714
◽
Keyword(s):
Keyword(s):
2017 ◽
Vol 71
(9)
◽
pp. e12987
◽
Keyword(s):
2010 ◽
Vol 32
(5)
◽
pp. 896-908
◽
Keyword(s):
2003 ◽
Vol 25
(7)
◽
pp. 2006-2021
◽
Keyword(s):
2005 ◽
Vol 22
(4)
◽
pp. 399-405
◽
Keyword(s):